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Abstract
Neoplasms change over time through a process of cell-level evolution, driven by genetic and 
epigenetic alterations. However, the ecology of the microenvironment of a neoplastic cell 
determines which changes provide adaptive benefits. There is widespread recognition of the 
importance of these evolutionary and ecological processes in cancer, but to date, no system has 
been proposed for drawing clinically relevant distinctions between how different tumours are 
evolving. On the basis of a consensus conference of experts in the fields of cancer evolution and 
cancer ecology, we propose a framework for classifying tumours that is based on four relevant 
components. These are the diversity of neoplastic cells (intratumoural heterogeneity) and changes 
over time in that diversity, which make up an evolutionary index (Evo-index), as well as the 
hazards to neoplastic cell survival and the resources available to neoplastic cells, which make up 
an ecological index (Eco-index). We review evidence demonstrating the importance of each of 
these factors and describe multiple methods that can be used to measure them. Development of 
this classification system holds promise for enabling clinicians to personalize optimal 
interventions based on the evolvability of the patient’s tumour. The Evo- and Eco-indices provide 
a common lexicon for communicating about how neoplasms change in response to interventions, 
with potential implications for clinical trials, personalized medicine and basic cancer research.
Neoplasms evolve1–3. This evolution has been recognized since 1976 (REF. 4), and it 
explains the processes of both carcinogenesis and acquired therapeutic resistance1. The 
evolution of neoplasms is shaped by the selective pressures of their microenvironmental 
ecology. But between and within cancer types, tumours probably display differences in the 
dynamics of cancer evolution and ecology, including the rates at which new clones appear 
and go extinct, how different those clones are from one another and whether they appear in 
bursts or at a more regular pace. Many of the evolutionary and ecological properties of a 
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neoplasm are clinically relevant5–16, though this is not always true6,16,17, and in most cases 
their clinical relevance has not yet been tested. There is a need for a common language and 
conceptual categories for drawing clinical distinctions that capture the relevant genetic, 
environmental and kinetic parameters that impact tumour adaptation and progression, as 
well as response to therapy. A classification system for the evolution and ecology of 
neoplasms would provide clinicians and researchers with a foundation for developing better 
prognostic and predictive assessments of tumour behaviour, such as response to an 
intervention.
The ultimate purpose of a classification system for the evolution and ecology of neoplasms 
is to provide a descriptive tool by which to improve clinical management with respect to the 
overall survival and quality of life of the patient. It would also help to drive research and 
discovery in cancer biology and oncology.
Below, we discuss the methods by which we reached consensus as well as the goals and 
guiding principles we aspired to in the development of a framework for classifying 
neoplasms. We then discuss each of the components of the classification system as well as 
methods for measuring them and for dividing tumours into an initial set of 16 classes. We 
discuss how such a classification system could be developed, improved and used clinically 
in the future.
Methods
We convened a consensus conference of experts in the fields of cancer evolution and cancer 
ecology to lay the groundwork for the development of an evolutionary and ecological 
classification system. The initial participants (Maley, Aktipis, Graham, Sottoriva, Boddy, 
Janiszewska, Silva, Gerlinger, Anderson, Brown and Shibata) were among the faculty for the 
Evolution and Ecology of Cancer summer school funded by Wellcome and held at the 
Wellcome Genome Campus in Hinxton, UK, in July of 2016. Input from all participants was 
solicited, and after discussion, we identified areas of consensus. Afterwards, other leaders in 
the field were invited to join the effort by co-editing and discussing the developing 
statement. All authors reviewed and approved the final statement. Wellcome Genome 
Campus Advanced Courses and Scientific Conferences provided financial support for the 
consensus meeting. We have named the classification system, with their permission, in 
appreciation of Wellcome’s support. Please note that the statement reflects the opinions of 
the authors and not necessarily those of Wellcome.
Goals and guiding principles
Our development of this framework has been guided by several goals and principles. We 
agreed that an ideal classification system should have the following properties. First, it must 
be able to alter a clinical decision point. Second, it should be simple enough to be easily 
remembered and applied. Third, it should also align with our current understanding of the 
dynamics of neoplasms. Fourth, the classification system should be general enough to be 
applied across different types of neoplasm, recognizing that the types of measurement may 
need to be individualized to a given type of cancer.
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This framework is based on fundamental theoretical principles underlying evolutionary and 
ecological dynamics. It is not based on any particular assay or parameter but rather captures 
the fundamental drivers of tumour evolution. This is a necessary first step that we hope will 
lead to many methodological and measurement innovations to quantify the key components 
of tumour evolution and ecology that we identify here. Because the evolution of cancer is 
still a relatively new field, there is still uncertainty about the best ways to measure and 
describe the evolution and ecology of a tumour.
There are also practical considerations in the construction of a classification system. If a 
tumour could be classified based on a single biopsy from standard assays such as those that 
can be done on formalin-fixed paraffin-embedded (FFPE) tissue or standard radiological 
images, translation to the clinic would be relatively easy. However, studies have not yet been 
done to test whether measures of the evolvability of a tumour from a single biopsy sample 
are sufficient or whether multiple samples substantially improve predictions of clinical 
outcomes15. We hypothesize that we will need to extensively sample neoplasms over both 
space and time in order to accurately quantify their evolvability, but this remains an open 
question. It is clear, however, that evolutionary analyses are limited if the clonal structure of 
the primary tumour is unknown18. The use of cell-free DNA (cfDNA) from liquid biopsy 
samples should facilitate longitudinal studies19, although deconvoluting the clones within 
such a mixed sample remains a challenge20.
Framework for classifying tumour evolution
There are many well-established ways to classify tumours, largely based on extent of spread 
and morphological appearances (for example, stage and grade). An evolutionary 
classification system would augment current schemes by further capturing the evolvability of 
a tumour. How much intrinsic genetic instability does it have? How likely is it to respond 
quickly to a new selective pressure such as a therapeutic intervention? For example, rapid 
progression after chemotherapy is probably driven by pre-existing resistant variants, and 
therefore, failure is more likely in tumours with more subclonal diversity (intratumoural 
heterogeneity)6. Moreover, it would be useful to classify evolution through time. For 
example, a second biopsy from the same patient after therapy may reveal minimal diversity, 
indicating a recurrent tumour derived from a single clone, or substantial diversity, suggesting 
intrinsic resistance by the majority of tumour cells. There was widespread agreement at the 
consensus conference that both the evolutionary dynamics of the neoplastic cells themselves 
(cancer cell intrinsic factors) and the microenvironment that defines the ecology of those 
cells (cancer cell extrinsic factors) are important in predicting the future behaviour and 
response of a tumour. To capture this, we have developed a framework for both an 
evolutionary index (Evo-index) that describes the intrinsic evolvability of the neoplastic cell 
population and an ecological index (Eco-index) that describes potential selective pressures 
imposed by the surrounding microenvironment.
The Evo-index
The Evo-index (D#Δ#) is a combination of two fundamental components: the diversity (D) 
or intratumoural heterogeneity of the neoplasm and how it changes over time (Δ). In other 
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words, the Evo-index quantifies heterogeneity in both space and time (FIG. 1a). Both 
diversity and changes in the clonal structure of a tumour over time are objective measures 
and may be assessed as part of preclinical studies or clinical trials.
Diversity
The heterogeneity that is currently present in a population defines its capacity to respond, at 
a population level, to selective pressures. This diversity is the fuel for the engine of natural 
selection. There are different forms of diversity, including genetic diversity, epigenetic 
diversity, phenotypic diversity and functional diversity. Genetic diversity can predict 
progression to invasive cancers12,13 as well as recurrence and survival5–9,16. The relationship 
between diversity and clinical outcomes is not universally consistent across different cancer 
types6,16 and can be complicated (BOX 1).
Box 1
Important issues in the measurement of diversity in neoplasms
There are a number of important issues and open questions in the measurement of 
diversity in neoplasms: How are clones defined? What is the best measure of diversity? 
How do the measures scale up to genomic assays? Are there nonlinear associations 
between diversity and clinical outcomes? Is genetic or functional diversity more 
predictive? Is it sufficient to measure diversity in the primary tumour, or do we need to 
measure diversity in the metastases? Is it adequate to estimate diversity from bulk biopsy 
assays, or do we need to measure diversity at the single-cell level?
In order to measure diversity, one must first define the unit that is being measured. We 
typically cluster cells into clones, but there is currently no general definition of a clone. 
Typically, for expediency, clones are defined as the set of cells that share an alteration of 
interest, due to descent from a common ancestor cell. A more stringent definition of a 
clone is a set of cells that have the same genotype based on some assay12,13. However, 
that definition does not scale well to whole-genome assays because every neoplastic cell 
probably displays a unique genome. By contrast, measures of divergence between 
samples only become more accurate as assays scale up to the genomic level12–14,46. 
Another alternative would be to reconstruct the cell lineage (phylogeny) of a neoplasm 
and then define clones based on the topology of the cell lineage, although this is not 
straightforward. A similar problem has been addressed by viral and bacterial 
phylogenetics, and methods may be borrowed from these fields167,168.
It is not clear which alterations should be used to measure diversity. Some forms of 
diversity, such as mutations in exons and copy number changes, may be more clinically 
relevant than other forms of diversity. However, Merlo and colleagues found that defining 
a clone based on selectively advantageous mutations and defining a clone based on 
evolutionarily neutral mutations both predicted progression to cancer13.
Instead of genetics, one could measure diversity based on RNA expression or other 
phenotypic characteristics169,170. Because selection acts on phenotypes, this may be a 
better predictor of a the evolvability of a tumour than genetic measures of diversity. 
Gatenby and colleagues have argued that because of this and the fact that there are many 
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different genotypes that can produce the same phenotype, analysis at the phenotype level 
may be easier and provide a better measure of evolvability than analysis at the genotype 
level171,172. However, this hypothesis is controversial, and only a few studies have tested 
it173,174. Unfortunately, the literature on how to measure functional diversity remains 
poorly developed30.
The diversity of the primary tumour may differ from that of any metastases. Because the 
primary tumour is often removed and it is the metastases that kill patients, we may have 
to measure diversity within and between any metastases that can be sampled in order to 
best predict clinical outcomes2.
It is currently difficult to measure many loci or phenotypes at the single-cell level. Bulk 
sequencing or other assays at the biopsy level introduce significant biases. For example, 
recent mutations that are present in only a single cell or a small minority of cells are 
missed in bulk assays, biasing results to the early mutations and those mutations driving 
clonal expansion175. Preliminary analyses show that a mixture of clones within a biopsy 
sample can also mislead any analyses based on estimates of shared ancestry, such as 
phylogenetic reconstruction176. However, it is currently difficult to assay enough loci in 
enough single cells to reconstruct reliable cell lineages and identify rare clones177.
Diversity can be a proxy for the likelihood that a resistant clone is present in a neoplasm. We 
currently do not know all the mutations and epigenetic alterations that make a neoplastic cell 
resistant to a particular therapy, and even those we do know are difficult to detect if they are 
present in only a small region of the tumour. Compared with homogeneous neoplasms, 
diverse neoplasms are more likely to harbour resistant clones and are also probably more 
likely to evolve resistance in the future.
Multiple forms of diversity within a neoplasm may be clinically important, not only as fuel 
for natural selection but also as biomarkers of clinically targetable dynamics. For example, if 
high levels of genetic diversity are indicative of high levels of moderately deleterious 
passenger mutations21,22, then suppressing mechanisms in the cell that buffer against those 
deleterious effects, such as chaperone proteins, should preferentially harm neoplastic cells21. 
Alternatively, diversity may be indicative of cooperation between clones, through 
mechanisms such as cross feeding23–27. These mechanisms of cooperation are themselves 
potential therapeutic targets. Theory suggests that targeting cancer cell cooperation should 
provide weaker selection for resistance than cytotoxic therapies28.
It is likely that not all forms of diversity are equal, and future work must test which are 
clinically relevant. It may be the case that measures of functional diversity or even 
phenotypic diversity are better predictors of clinical outcomes than measures of genetic 
diversity (as many genetic mutations will have no phenotypic consequence), and the ideal 
measures may vary between tumour types.
Measuring diversity
Of the four components of the classification framework, the largest number of methods has 
been developed for measuring diversity (intratumoural heterogeneity)13,25,29 (TABLE 1). 
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There is a large literature in ecology on the quantification of diversity30. The overall 
diversity of a large area, or landscape (gamma diversity), can be broken down into the 
diversity within local regions (alpha diversity) and the differences between regions (beta 
diversity)31. Inherent in this definition is the concept that measuring diversity requires 
defining the spatial scale that one is examining. One might define within-region diversity as 
the diversity measured within a biopsy sample, while between-region diversity would 
account for differences between biopsy samples in multi- region sampling studies. 
Alternatively, one could take a sample across an entire tumour, perhaps using cfDNA, and 
estimate the diversity of the entire population. Most of the studies to date have focused on 
within-region diversity5,6,32,33 or the diversity of the entire tumour12–14,25. The use of 
ecological statistics for measuring between-region diversity in tumours remains relatively 
unexplored. Established measures of differences between microbial communities34 could 
possibly be applied to measuring differences between biopsy samples.
There are many ways to measure diversity30 and a number of challenges to measuring 
diversity in neoplasms, as discussed in BOX 1. In Barrett oesophagus, Merlo and colleagues 
tested many of those measures of diversity and found that high levels of diversity were 
predictive of progression to cancer, regardless of the measure13,14. Because evolution is 
driven by the fitness outliers35, and it may take only one resistant cell at diagnosis to 
eventually cause drug resistance or relapse after therapy, much of the predictive value of 
measuring diversity may lie in the long tail of rare clones. Because of this, we recommend 
using either a count of the number of clones (‘species richness’) or Shannon index, which 
equally weights number and relative abundance of clones, to quantify diversity30.
The feasibility of obtaining a complete picture of the diversity of a neoplasm, through multi-
region sampling or cfDNA, varies across tumour types. In Barrett oesophagus, bladder 
cancer and prostate cancer, multi-region sampling is part of the current standard of care36–38. 
In a well-mixed neoplasm, such as a blood cancer, a single sample may be sufficient, but it 
requires single-cell assays, which have their own challenges (BOX 1). In other tumours that 
are difficult to sample, such as pancreatic cancers, we are lucky to get more than one biopsy 
sample. The main challenge in using cfDNA is detecting it in serum for cancers that have 
not yet metastasized, although the level of tumour cfDNA in serum varies across cancer 
types. A recent study was able to detect tumour cfDNA in 97% of early-stage lung 
squamous cell carcinomas but only 19% of early-stage lung adenocarcinomas39.
The interpretation of the diversity of a neoplasm depends on the context of its history. A 
neoplasm that has just been homogenized by a therapy that killed most of the clones in that 
neoplasm is different from a neoplasm that is homogeneous because it has a very low 
mutation rate and has not had enough time to accumulate many clones. By contrast, a high 
level of diversity in a neoplasm that has just passed through a therapeutic bottleneck may be 
a sign that therapy selected for a mutator phenotype40. Because of this complication, we 
agreed that we must measure how neoplasms are changing over time as well as diversity.
Change over time
There are a variety of ways that a neoplastic cell population changes over time. These 
include mutations, natural selection and genetic drift. One important parameter of change 
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over time is the mutation rate, which describes how fast a lineage accumulates new 
mutations. Of course, there are different mutation rates induced by each mechanism for 
genetic and epigenetic alteration, including mutation signatures induced by specific agents41 
as well as telomere erosion, non-homologous recombination, other forms of chromosomal 
instability, CpG methylation and his-tone modifications. Which mechanisms are relevant 
will depend on individual tumours and may vary across the different clones within the same 
tumour.
When we talk about and measure mutation rates, we are implicitly assuming that mutations 
happen at a regular rate. Evolutionary biologists call these ‘molecular clocks’ (REF. 42). 
However, a catastrophic mitosis can generate chromosomal alterations across the genome in 
a single event43,44. There is a continuum from regular, gradual, clock-like small alterations 
to sporadic, punctuated, large alterations. For example, a lineage may evolve different 
mutation rates across its history, as happens with the evolution of a mutator phenotype45,46. 
If a cell lineage can change suddenly, in what used to be called a ‘macromutation’ 
generating a ‘hopeful monster’ (REF. 47), then that tumour may have a different capacity for 
evolution compared with a tumour that is constrained to evolve through the slow 
accumulation of mutations with small phenotypic effects. There is a large cancer literature 
on genetic instability that is relevant here48,49, and evidence has shown that tumours with 
extremely high mutation rates may have a better prognosis than tumours with moderate 
rates6,11,21,22,50. High levels of genomic instability may make it difficult for cell lineages to 
maintain the adaptive information encoded in their genomes, generating non-viable daughter 
cells, and may also produce an abundance of neo-antigens that stimulate an antitumour 
immune response6. Furthermore, high mutation rates of single nucleotide variants can 
generate deleterious mutations, leading to the fitness decline of neoplastic cell lineages in a 
form of Muller’s ratchet21,51. This may even cause tumour regression in some cases21,22.
The genetic composition of a population changes over time not only through the rate at 
which mutations arise and the genetic drift of those alleles but also through the action of 
natural selection. Natural selection leads to adaptations, such as drug resistance52, that are 
clinically relevant. Detecting and measuring natural selection is likely to be an important 
component of our future clinical management of cancers.
The classification of a neoplasm’s change over time (Δ) will probably need to take into 
account both the speed at which a tumour acquires genetic or epigenetic alterations, or 
changes phenotypically, including how fast clones spread by natural selection, as well as the 
tempo of that change (from gradual to punctuated). The appropriate intervals for 
longitudinal sampling will depend on the rate of change over time53. Note that neutral, or 
‘passenger’, mutations should not be ignored in these calculations because selective 
pressures change over time, particularly with the onset of therapy. Thus, resistance 
mutations, which may be deleterious or neutral in the absence of therapy, can become 
selectively advantageous for neoplastic cells exposed to therapy54.
Measuring change over time
Measuring change over time is complicated, whether it is genetic or phenotypic change 
(TABLE 1). FIGURE 1b illustrates a simple version of how the Evo-index can describe 
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evolutionary changes in tumour cell populations. It is possible for there to be change over 
time but for diversity to remain stable, with a dynamic equilibrium of clones appearing and 
going extinct14. For single samples, past genetic changes over time can be indirectly inferred 
based on mutation frequencies17,55. Sottoriva and Graham have pioneered methods to infer 
the mutation rate and to distinguish between tumours that are dominated by genetic drift 
versus those with evidence of natural selection after transformation. In the absence of 
selection, mutations that occur in the first cell division after transformation should appear in 
approximately one-half of all cancer cells, mutations that occur in the second round of cell 
division should appear in one-quarter of all cancer cells, and so on17,56.
There are a number of measures of genetic change over time from population genetics that 
might be used on neoplasms, including Nei’s standard genetic distance57,58 and the Jaccard 
similarity coefficient59, as well as measures of beta diversity that can also quantify changes 
in a community over time, such as UniFrac34 or the fixation index60. The degree of genetic 
divergence between samples (called ‘nucleotide diversity’ in molecular population genetics) 
provides indirect information on the degree of change over time. Genetic divergence is often 
defined as the percentage of the genome that is different between pairs of samples12–14. This 
statistic provides predictive power independent of the number of clones for predicting 
progression12,13, supporting the framework of including both diversity and change over time 
in the Evo-index. Note that the same clonal structure can have radically different degrees of 
genetic divergence (FIG. 2). Maley and colleagues have calculated a mean pairwise 
divergence score between all pairs of samples from a neoplasm12–14. As the chance that two 
samples come from the same clone (and so have minimal divergence) depends on the size of 
the clone, the mean pairwise divergence blends the degree of divergence with clone size 
measures (and so blends D with Δ).
One of the primary tools for measuring change over time in evolutionary biology is 
phylogenetic inference, which reconstructs the history of a neoplasm61,62. Phylogenetic 
methods can be used to describe and quantify diversity patterns as well as rates of evolution 
across both space and time. Multiple phylogenetic approaches have been developed in recent 
years to study tumour evolution within a patient, both for bulk and single-cell data and from 
a variety of data types20,63. These methods depend on evolutionary models for the likelihood 
of molecular alterations occurring in neoplastic cell lineages, although the development of 
these models is still in its infancy.
All of the measures discussed so far can be calculated from a single timepoint. Of course, 
the degree and nature of change over time can be better measured directly with longitudinal 
samples. Minimally invasive assays, such as sequencing cfDNA from longitudinal blood 
samples, could reveal the action of natural or artificial selection in patients.
Incorporation of the Evo-index into clinical trials can better describe, in evolutionary terms, 
why interventions fail. Most human tumours at the time of clinical presentation contain 
multiple large clones6,16 and probably many more small clones64,65, and relapse without a 
reduction in diversity would probably imply intrinsic resistance or perhaps that an 
intervention resulted in increased mutagenesis. By contrast, relapse with less diversity (D1) 
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implies a bottleneck effect where only a minority of tumour cells survived the intervention, 
probably indicating selection for one or a few resistant clones.
The Eco-index
From the perspective of an organism or a neoplastic cell, its ecology can be broadly 
described by two characteristics: hazards (H) and resources (R)66–69 (FIG. 3). Hazards, here, 
are the things that can kill a cell. The relevant resources required for cell maintenance and 
growth are many and varied; whatever may potentially limit the growth of the neoplastic cell 
population66. Note that hazards and resources here are understood from the perspective of 
the neoplastic cell, not the patient. This is an important point from ecology —we can 
understand the evolution and responses of a population best when we take the perspective of 
an organism in that population70.
From an ecological perspective, the hazard and resource profiles for a species select for the 
particular life history strategies of that species. Aktipis and colleagues argued that the same 
principles are true for neoplastic cells71. Species that are exposed to high levels of hazard 
tend to evolve fast life history strategies, reproducing quickly and investing little in 
maintenance and survival. Organisms subjected to hazards generally leave behind higher 
levels of unexploited resources. Ecosystems with high or fluctuating resource supplies 
favour organisms that can rapidly reproduce to exploit those opportunities. This selects for 
speed over efficiency and can result in very high population densities but also fluctuating 
levels of unexploited resources. By contrast, populations that have few hazards and a steady 
supply of resources will tend to expand to the carrying capacity of the habitat, at which point 
natural selection favours organisms that can best compete for and efficiently utilize the 
limiting resources72. The heterogeneity of resources and hazards across space also has 
important impacts on the future evolution of cancer cell populations and prognosis for 
patients73,74.
Hazards
There are multiple sources of hazards for neoplastic cells, including immune cells, toxins, 
waste products, microorganisms and anticancer therapies. There is good evidence that 
immune predation is associated with improved cancer prognosis73,75–83. Furthermore, there 
is emerging evidence linking high mutation loads that result in the formation of neo-antigens 
with immune predation and better survival in patients treated with immune checkpoint 
blockade therapies84–86. In addition, a high subclonal neo-antigenic burden is associated 
with worse outcomes in lung cancer when patients are treated with checkpoint inhibitors87. 
These data suggest that subclonal neo-antigens might impede cytotoxic immune responses 
against neo-antigens that are present in every tumour cell.
Other hazards faced by neoplastic cells include the accumulation of waste products in their 
micro-environments67,69,88,89. This may include lactic acid and lactate build-up from 
glycolysis88,90 as well as reactive oxygen species from excessive cellular proliferation91. 
Methylglyoxal92,93, nitric oxide94,95 and advanced glycation end products96,97 have also 
been implicated as toxic waste products in cancer microenvironments.
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The role of the microbiome in cancer is complicated and largely unknown. While some 
microorganisms may promote tumours98,99, others have antitumour effects98, enhancing the 
efficacy of chemotherapy100. Thus, micro-organisms may act as both resources and hazards 
for neoplastic cells.
Measuring hazards
The current best measures of hazards for a neoplastic cell depend on measures of immune 
predation (TABLE 1). There is a large literature on the association between infiltrating 
lymphocytes and favourable prognosis in cancer73,75–83. In addition, a pan-cancer analysis 
revealed T cell signatures to be broadly favourable prognostic markers across 25 cancer 
types101. Galon and colleagues have found that a signature of activated T cells from bulk 
tumour samples is also strongly predictive of favourable survival76–78,83. Yuan and 
colleagues have shown that haematoxylin and eosin images can be computationally analysed 
to identify neoplastic cells, fibroblasts and lymphocytes and, furthermore, that patients with 
breast cancer who show colocalization of neoplastic cells with lymphocytes in the tumour 
have a better prognosis than patients with tumours in which the lymphocytes are separated 
from the neoplastic cells75. This is based on a standard ecological statistic, the Morisita–
Horn index102, for quantifying statistically significant colocalization in order to detect 
ecological interactions (in this case, predation). These results suggest that immune predation 
is a major form of hazard for a neoplastic cell, and measures of that predation should be a 
central component of the ecological index.
While much research has investigated the potentially toxic effects of low pH (REFS 
103,104), fewer studies have examined the fitness consequences to cancer cells from various 
metabolites. Future research should determine the effects of different concentrations of 
putative toxic metabolites on cancer cell survival and proliferation in both cell culture 
experiments and mouse models. Measurements of anticancer drug concentrations in the 
tumour are also likely to quantify important hazards for the neoplastic cells. In addition, the 
microbiome (including the virome) of tumours can be surveyed to reveal microbial hazards 
for the neoplastic cells105.
Resources
Resources, including oxygen, glucose, micronutrients, survival signals, growth signals and 
space, are also critical to the future behaviour of a tumour. Surprisingly little is known about 
the interactions between cell metabolism and the availability of key resources, which 
ecologists term the organism’s ‘foraging ecology’. Almost all cancers rely on glycolytic as 
opposed to aerobic metabolism, suggesting that resources can select for tumour 
phenotypes106,107. From nature, we know that selection favours feeding behaviours that 
balance speed, efficiency and safety108. There must be strong selection for cancer cells to do 
the same (for example, through upregulation of transporters such as glucose transporter type 
1, erythrocyte/brain (GLUT1, also known as SLC2A1)109). Measuring which resources limit 
the population size and proliferation of neoplastic cells would allow researchers to identify 
some of the strongest selective pressures on the tumour and to predict how it will change in 
the future. This approach would also provide targets for further reducing the evolvability of 
the neoplasm by lowering the carrying capacity of its microenvironment.
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In the broader ecological literature, consumer–resource theory110 shows that resource 
supply, depletion and availability affect population growth rates, population sizes and 
competition between different species (that is, distinct clonal lineages). Resource supply 
represents the rate at which new resources enter the system (in this case, the tumour) and the 
rate at which resources become available through nutrient cycling within the system. The 
aggregate consumption of all cells depletes the resources, typically to levels much lower 
than experienced by normal tissues111. In fact, glucose becomes depleted below levels 
detectable by most analyses112. However, in some cases, immune predation and fluctuations 
in resource supply can prevent the complete exploitation of resources113,114, leaving patches 
of residual resources available for future exploitation115.
The potential resources for a tumour include the contents of plasma and the metabolites 
synthesized and secreted by the normal cells of the tumour and its microenvironment. 
Hence, the list includes proteins (albumins, globulins and fibrinogens), glucose, amino acids, 
fatty acids, hormones, electrolytes, oxygen and trace elements. The functional response and 
the value of the resources to the consumer are dictated by nutritional relationships116. In 
some cases, lack of a resource may trigger stasis, but in others, it may lead to cell death or 
dispersal117. At the moment, there are many open questions about the intratumoural cycle of 
critical nutrients other than carbon and nitrogen (that is, phosphate, iron, copper, etc.)118. 
These nutrient cycles may contain valuable therapeutic targets.
Some resources, particularly growth and survival signals, may be provided by the 
neighbouring stromal cells119,120. Nutrients may also be provided by the stroma. Pyruvate 
and lactate can be supplied to cancer cells by activated fibroblasts121,122, and fatty acids may 
be supplied by activated adipocytes123,124. Tumour and stroma only come into physical 
contact when the basement membrane is breached by malignant neoplastic cells. At this 
stage, cancer cells can directly interact with cancer-associated fibroblasts, which are known 
to play a key role in the regulation and development of tumours, especially solid 
tumours120,125. In this secretory reactive state, fibroblasts facilitate not only cancer growth 
and progression126,127 but also treatment resistance128. In addition, their presence in a 
tumour has been correlated with poor outcomes129.
Other resources must be delivered through the vasculature. Folkman made the crucial link 
between angiogenesis and tumour invasion and metastasis, realizing that preventing new 
vessels from forming could be a simple way to inhibit further tumour growth130,131. The 
presence in many tumours of necrosis and hypoxia, which are major drivers of angiogenesis, 
attests to the importance of resource limitation in tumours. Furthermore, there is evidence 
that necrosis is a prognostic factor in many cancers132.
The effects of resources on the evolution of a tumour are not defined simply by their supply, 
depletion and availability. Resource diversity may also be important. Whether resources are 
uniform across space or heterogeneous (‘patchy’ or exhibiting gradients) makes a 
difference67,133. Patchy resources (and hazards) create multiple habitats (for example, rich 
and sparse regions) that may select for different clones that can survive in those regions and 
may be differentially responsive to (and differentially exposed to) therapies. Furthermore, 
we and others have shown that if those patchy resources change over time, then there is 
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selective pressure on cells to move to escape regions of scarce resources and exploit 
transient regions of more plentiful resources67,113,114,134–136. Thus, ecological theory 
predicts that heterogeneous resources should select for invasion and metastasis134,135, and 
there is evidence to support that prediction in cancer137–143. Verduzco and colleagues found 
that intermittent exposure of some cell lines to hypoxia selected for increased resistance to a 
variety of chemotherapies, including etoposide, docetaxel and methotrexate, compared with 
unselected controls144. In addition, resource gradients often lead to rapid evolution, as 
organisms that are able to invade more stressful environments can escape competition and 
flourish145. Much needs to be learned about resource heterogeneity, consumer–resource 
dynamics and the foraging ecology of neoplastic cells.
Measuring resources
Measuring resources (and hazards) requires the consideration of relevant spatial and 
temporal scales. It is not yet clear how to combine measures of the level of resources, their 
spatial variance and their stability over time into a single statistic.
There are various resources and methods to measure them that may be prognostically 
relevant (TABLE 1). The proportion of a tumour that is necrotic or poorly perfused may be 
read from standard positron emission tomography and computed tomography (PET–CT) 
images146 and through other measures of blood vessel density147,148. The degree and 
patchiness of hypoxia can also be assayed in FFPE samples with antibodies against carbonic 
anhydrase 9 (CA9) or hypoxia-inducible factor 1α (HIF1α)115 or via intravenous 
introduction of 2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3- pentafluoropropyl) acetamide 
(EF5) and the subsequent measurement of its binding in the tumour tissue149. EF5 binding 
and related techniques have proved useful in the clinic for detecting regions of hypoxia, 
determining prognosis and measuring response to therapy150. While it is difficult to measure 
glucose concentration directly, an indirect measure may be made via immunohistochemistry 
staining for expression of GLUT1115. Measures of ATP may also be a good indirect measure 
of the amount of resources available to neoplastic cells151. Glutamine, pyruvate, lactate, 
fatty acids, calcium, potassium, phosphorus and various trace metals may also be limiting 
and important to measure, but this appears to be unexplored. Most of these measures will be 
limited to biopsy samples analysed ex vivo and thus will suffer the problems of spatial 
heterogeneity and sampling error.
In some cases, the problem of spatial heterogeneity and sampling error can be avoided 
through gross measures of resources from radiological images152–154 Radiographic images 
such as those obtained using PET–CT and magnetic resonance imaging (MRI) can provide 
valuable habitat data. In natural systems, there is usually a tight correlation between habitat 
and the types and characteristics of species inhabiting the habitat. Similarly, simply knowing 
the different habitat types within a tumour may be prognostic of the community of cancer 
cells and therapeutic outcomes. For instance, in glioblastoma, measures of fluid-attenuated 
inversion recovery (FLAIR), T1 and T2 from MRI examinations after gadolinium 
administration identified distinct habitats that correlated with therapeutic outcome, 
independent of tumour size153. Texture analysis of MRI scans has been used to identify 
spatial heterogeneity and regional variations that are associated with microenvironmental 
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conditions, including cell density, tissue stiffness, blood flow and nutrient dispersion152,154. 
These may also be used to measure functional diversity (D) in tumours. Geographic 
information systems (GIS)155–157 and ecology158 provide a rich literature and a source of 
tools for analysing spatial resource information, but these are rarely utilized in cancer 
research73,74.
Standard histopathology can provide measures of T cell infiltration and vascular and 
lymphatic density77. Using digital pathology, Lloyd et al. investigated the spatial 
distributions of oestrogen receptor (ER) expression in relation to vascular density and tissue 
necrosis in breast cancer histology specimens, revealing considerable regional variations in 
cancer proliferation phenotypes accompanied by vascularity and immune response115,159. 
Yuan and colleagues also used digital pathology to analyse the spatial relationships between 
fibroblasts and neoplastic cells160. We have summarized the statistics and assays for 
measuring diversity, change over time, hazards and resources in TABLE 1.
Categories of tumours
The future behaviour of a tumour depends on both its evolutionary potential (the Evo-index) 
and the selective pressures on the tumour (the Eco-index). A highly evolvable tumour may 
or may not evolve immune evasion depending on whether the immune system is imposing a 
strong selective pressure on the tumour. By contrast, an immune response may or may not 
lead to immune evasion depending on the evolvability of the tumour. Thus, both the 
evolution and ecology of a tumour must be considered in predicting cancer outcomes. We 
therefore propose to combine the Evo- and Eco-indices to classify tumours. Dichotomizing 
each evolutionary and ecological factor of the Evo- and Eco-indices into high and low values 
would produce 16 possible types of tumour (TABLE 2).
In order to classify a tumour, investigators will first need to define and validate clinically 
relevant thresholds for dichotomizing diversity, change over time, hazards and resources 
(TABLE 1). For example, in Barrett oesophagus, Maley and colleagues found that the upper 
quartile of diversity statistics distinguished patients who are likely to progress to 
oesophageal adenocarcinoma12–14. Once those thresholds are validated, a tumour would be 
measured for each of the four evolutionary and ecological factors to determine which of the 
16 types it falls into. For example, if a tumour was below the thresholds for all four factors 
(that is, a D1Δ1H1R1 tumour), it would be a type 1 tumour.
A roadmap for improvements
We are not yet in a position to specify which measures and thresholds should be used to 
determine the D#Δ# or H#R# type of a tumour. Initial studies should test if these 
classifications significantly predict clinical outcomes and which evolutionary and ecological 
measures provide independent predictive value. They should also test if there are measures 
that can apply across cancer types or if they have to be uniquely defined for specific organs 
or tumour subtypes. Future studies should test alternative measures of diversity, change over 
time (BOX 2), hazards and resources to help standardize useful metrics for the 
classifications. They should also quantify the improvements to prognosis gained by 
sampling multiple regions at multiple timepoints.
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Box 2
The future of the Evo-index
Our framework for quantifying the evolvability of a neoplasm is based on the diversity 
within the tumour and how that diversity changes over time. Diversity and genetic change 
over time are the easily observable results of the underlying evolutionary dynamics. A 
future evolutionary index (Evo-index) may be based on the parameters that determine the 
rates of evolution15:
• Mutation rate17,178
• Population size of the self-renewing neoplastic cells (also known as ‘cancer 
stem cells’), which are the units of evolutionary selection in cancer3
• Generation time of the self-renewing neoplastic cells
• Selective coefficients17,179 or clonal expansion rates14
• Heritability of selectively advantageous phenotypes
Most of these parameters are currently difficult to measure. However, there is already 
good evidence that the number of self-renewing cells in a tumour is associated with 
adverse outcomes180,181, that self-renewing cell frequency increases with 
progression182,183 and that self-renewal signalling pathways are actionable and effective 
targets for therapy184,185. This is probably true for all types of tumour. Assaying self-
renewing cells functionally (by xenotransplantation) is difficult, but quantifying stem cell 
signatures is possible. However, stem cell phenotypes are not stable and can be 
modulated both by genetic changes and (epigenetically) by ecological conditions (for 
example, hypoxia)3, suggesting that the importance of any one parameter is also a 
function of its heritability.
The ecology of a tumour affects its evolution, and the evolution of the cells in a tumour 
change their ecology. Neoplastic cells evolve genomic instability161, generating neo-
antigens as well as adaptations, such as recruitment of resources, through activating 
fibroblasts162 and neo-angiogenesis161. Evolution of neo-antigens triggers immune 
predation, which may reduce diversity and select for immune evasion163. High levels of 
extrinsic mortality and resources select for rapid proliferation with little investment in 
somatic maintenance71. These interactions imply that not all possible combinations of 
ecological and evolutionary measurements are equally likely. We will probably be able to 
drop some of the 16 possible tumour types in TABLE 2 and focus on the subset of classes 
that present in the clinic.
The framework for a classification system that we have proposed could be incorporated into 
clinical trials, which could allow us to gather data on how the different types of evolving 
tumour respond to different types of intervention (FIG. 4). Clinical trials could then be 
developed to stratify treatment of patients based on the Evo- and Eco-indices of their 
tumours. We could use the results to develop guidelines for best practice in managing 
cancers.
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Vision of the future
In the future, the pathology report for a neoplasm could include its Evo-index and Eco-index 
classifications. Ideally, these classifications would provide ‘chessboard’-like scenarios 
where, based on the current evolutionary class of a tumour, one could anticipate how the 
tumour type will change with different possible therapeutic moves (FIG. 4). Clinicians 
would then be able to choose appropriate interventions for the evolvability of those 
neoplasms and would also be able to track whether the neoplasms change substantially in 
response to interventions. A D1Δ1 tumour or even a D1Δ2 tumour would be a prime 
candidate for aggressive therapy with curative intent. In fact, a D1Δ1 tumour may be so 
evolutionarily indolent as to not require any form of intervention. On the other hand, a D2Δ2 
tumour is likely to have multiple resistant sub-clones present at diagnosis, and future clinical 
trials should test if such a tumour can be managed through strategies that minimize the 
expansion of resistant sub-clones by exploiting their disadvantage in competition with 
sensitive subclones164. A legitimate clinical strategy might be to down-stage a tumour from 
a highly evolvable one to a much more clinically manageable class that could be contained 
in a non-lethal state indefinitely (FIG. 4b). If validated, the Evo- and Eco-indices could be 
used as surrogate measures for overall survival or disease-free survival.
Conclusions
The evolutionary biology of cancer is, clinically, in a similar state to psychiatry in the 
nineteenth century. At that time, there was no standard classification system for mental 
illness used by practitioners. Without such a classification system, it was difficult to even 
talk about the illness, let alone make progress, as a common language was lacking. With the 
American Medical Association’s Standard Classified Nomenclature of Disease published in 
1933 (REF. 165) and the first Diagnostic and Statistical Manual of Mental Disorders 
published in 1952 (REF. 166), no matter how flawed they were, diagnoses of mental 
disorders became standardized, which facilitated studies to refine both the classifications as 
well as the treatment of those disorders. Studies based on the same classification system 
were then comparable, which further facilitated meta-analyses and overall progress in the 
field.
We have diagnostic categories for types of tumour based on their tissue of origin and 
staging, as well as some molecular markers, but we have lacked a system for classifying the 
evolvability and ecology of a tumour, which help determine how it will respond to 
interventions and how it might best be managed. Evolutionary oncology requires a shared 
lexicon upon which to base discovery. We reached consensus on the proposed framework for 
a classification system to characterize evolutionary differences between tumours that is 
applicable across all cancer types. Importantly, an evolutionary classification system will 
facilitate future efforts to study this fundamental property of tumours to reveal implications 
for treatment.
Acknowledgments
The consensus conference was supported by Wellcome Genome Campus Advanced Courses and Scientific 
Conferences. C.C.M. is supported in part by US NIH grants P01 CA91955, R01 CA149566, R01 CA170595, R01 
Maley et al. Page 16
Nat Rev Cancer. Author manuscript; available in PMC 2018 February 13.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
CA185138 and R01 CA140657 as well as CDMRP Breast Cancer Research Program Award BC132057. M.J. is 
supported by NIH grant K99CA201606. K.S.A. is supported by NCI 5R21 CA196460. K. Polyak is supported by 
R35 CA197623, U01 CA195469, U54 CA193461, and the Breast Cancer Research Foundation. K.J.P. is supported 
by NIH grants CA143803, CA163124, CA093900 and CA143055. D.P. is supported by the European Research 
Council (ERC-617457- PHYLOCANCER), the Spanish Ministry of Economy and Competitiveness 
(BFU2015-63774-P) and the Education, Culture and University Development Department of the Galician 
Government. K.S.A. is supported in part by the Breast Cancer Research Foundation and NCI R21CA196460. C.S. 
is supported by the Royal Society, Cancer Research UK (FC001169), the UK Medical Research Council 
(FC001169), and the Wellcome Trust (FC001169), NovoNordisk Foundation (ID 16584), the Breast Cancer 
Research Foundation (BCRF), the European Research Council (THESEUS) and Marie Curie Network PloidyNet. 
T.A.G. is a Cancer Research UK fellow and a Wellcome Trust funded Investigator. E.S.H. is supported by R01 
CA185138-01 and W81XWH-14-1-0473. M. Gerlinger is supported by Cancer Research UK and The Royal 
Marsden/ICR National Institute of Health Research Biomedical Research Centre. M.Ge., M.Gr., Y.Y., and A.So. 
were also supported in part by the Wellcome Trust [105104/Z/14/Z]. J.D.S. holds the Edward B. Clark, MD Chair 
in Pediatric Research, and is supported by the Primary Children’s Hospital (PCH) Pediatric Cancer Research 
Program, funded by the Intermountain Healthcare Foundation and the PCH Foundation. A.S. is supported by the 
Chris Rokos Fellowship in Evolution and Cancer. Y.Y. is a Cancer Research UK fellow and supported by The Royal 
Marsden/ICR National Institute of Health Research Biomedical Research Centre. E.S.H. was supported in part by 
PCORI grants 1505–30497 and 1503–29572, NIH grants R01 CA185138, T32 CA093245, and U10 CA180857, 
CDMRP Breast Cancer Research Program Award BC132057, a CRUK Grand Challenge grant, and the Breast 
Cancer Research Foundation. A.R.A.A. was funded in part by NIH grant U01CA151924. A.R.A.A., R.G. and J.S.B. 
were funded in part by NIH grant U54CA193489. The findings, opinions and recommendations expressed here are 
those of the authors and not necessarily those of the universities where the research was performed, Wellcome or 
the National Institutes of Health.
Glossary
Clones
Sets of cells that share an alteration of interest due to descent from a common ancestor cell.
Selective sweep
The spread of a mutation through a population due to natural selection.
Phenotypic diversity
The variety of different cellular states present in a population of cells.
Functional diversity
The variety of life history strategies present in a population of cells.
Genetic drift
Change in allele frequencies due to sampling error of gene copies from one generation to the 
next. Genetic drift is stronger in smaller populations.
Muller’s ratchet
Accumulation of deleterious mutations in asexual populations. This accumulation is 
irreversible because in asexual populations, deleterious mutations cannot be purged through 
recombination.
Nei’s standard genetic distance (DS).
A measure of the genetic divergence between species or populations given their respective 
allele frequencies. When the mutation rate is constant, DS increases linearly with time, from 
zero to infinity. In a multiregional or longitudinal sequencing study, it would quantify the 
amount of genetic divergence between two regional or temporal biopsy samples.
Jaccard similarity coefficient
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The proportion of species or clones that are present in both regions compared with the 
number of species or clones observed in the union of both regions.
UniFrac
A measure of the difference between biological communities that takes into account the 
phylogenetic distances (relatedness) between community members as well as their relative 
abundances.
Fixation index (FST).
A population genetic measure that estimates the proportion of global genetic variability that 
can be explained by population structure. In a multiregional sequencing study, it would 
quantify how much of the intratumoural heterogeneity is due to differences between regional 
biopsy samples.
Life history strategies
Relative investments in and mechanisms of growth, reproduction and survival of specific 
organisms or cells.
Morisita–Horn index
A statistic for measuring the extent to which two species tend to co-occur in the same 
locales.
Selective coefficients
The relative differences in fitness between genotypes.
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Figure 1. The Evo-index and how it changes
a | The evolutionary index (Evo-index) is composed of two factors corresponding to 
heterogeneity over space (diversity, D) and heterogeneity over time (change over time, Δ). 
By ‘change’, we mean both change in the genetic, epigenetic and phenotypic alterations 
present in the population and change in the frequencies of those alterations in the neoplastic 
cell population. What measures of D and Δ are best is an open question. In addition, how 
these factors should be stratified into two, three or more classes is also an open question. 
Here, for simplicity, we provide examples of the kinds of dynamics that could be categorized 
into a simple 2 × 2 classification. b | The genetic composition of a tumour may change either 
slowly (Δ1) or rapidly (Δ2) in a variety of ways. On the left, a tumour may have low 
diversity (D1) at time 0 because it is a new tumour or there has been a recent homogenizing 
clonal expansion. That tumour may be quiescent and so appear substantially the same at 
time 1 (D1Δ1), or it may accumulate clones, some of which expand, to generate a diverse 
tumour by time 1 (D2Δ2). Alternatively, a tumour may be diverse (D2) at time 0 because it 
is old or has a high mutation rate and is evolving neutrally. At time 1, that tumour may have 
been homogenized by a selective sweep (D1Δ2) or may continue on its current trajectory 
with gradual turnover of its clones (D2Δ1).
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Figure 2. Clonal divergence is independent of clonal structure
The cell lineages from two tumours may have the exact same clonal structure when they are 
sampled at the far right but have radically different degrees of genetic divergence. If one 
tumour (part a) has a higher mutation rate or has been accumulating genetic alterations for a 
longer period of time because those cells had a common ancestor, it will have a higher level 
of genetic divergence than another tumour (part b).
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Figure 3. The Eco-index
sThe ecological index (Eco-index) is composed of two factors corresponding to the hazards 
(H) and resources (R) available to the neoplastic cells. These capture the broad categories of 
selective pressures on a population. We have included example phenomena in this figure that 
might be observed in the different combinations of the degrees of hazards and resources. For 
example, a tumour with low hazards (H1) and low resources (R1) might be relatively barren, 
with few infiltrating lymphocytes but also poor perfusion and few supporting cells. Such an 
environment would select for cells that can either survive on few resources or move to locate 
more resources. High levels of hazards (H2) should, according to life history theory71, select 
for rapid proliferation, evasion of predation, migration away from the hazards67 and little 
investment in cell (and DNA) maintenance. High levels of resources allow neoplastic cells to 
rapidly proliferate. Thus, an H2R2 tumour would probably undergo massive cell turnover as 
cells are killed by the hazards and replaced by their rapidly proliferating sisters.
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Figure 4. Changing the evolutionary class of a tumour through interventions
With the classification system outlined in TABLE 2, we could examine how different 
interventions move tumours between categories. a | In this example, chemotherapy can be 
mutagenic and can select for hypermutator clones, generating new clones and more 
diversity40,186,187. It can also kill endothelial cells and thus have an anti-angiogenic 
effect188, resulting in a tumour (type 13) with one of the worst predicted prognoses. This 
may partly explain why tumours that recur after chemotherapy are so difficult to control. b | 
Immunotherapy, if successful, may increase the predation hazards to the tumour and perhaps 
select for a subclone, reducing diversity. Targeted therapy, unlike chemotherapy, probably 
does not cause significant DNA damage and may further genetically homogenize the 
tumour. Anti-angiogenic therapy is designed to restrict the resources of the tumour. At the 
end of this example sequence, the tumour is in the most manageable, least evolvable 
category (type 3 in TABLE 2). Of course, chemotherapy, immunotherapy and targeted 
therapy may have different effects depending on the details of those therapies and their 
interaction with the clones in the tumour and their ecosystem.
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Table 1
Measures and assays for the factors that go into the Evo- and Eco-indices
Icon Factor Statistics Assays
High
Low
Diversity (D) • Divergence12–14,46
• Number of clones (richness)6,12–14
• Shannon index12–14
• Simpson’s index12,13
• Functional diversity115,169,170,61–63
• Phylogenetic trees20
• Whole-exome and whole-genome 
sequencing
• Multi-region sequencing
• SNP arrays
• Methylation arrays
• FISH
• Single-cell DNA and RNA 
sequencing
• Cell-free DNA sequencing19
• RNA-Seq
• Proteomics
• Radiology
High
Low
Change over 
time (Δ)
• Mutation rates17,178
• Estimates of selection17,179
• Clonal expansion rates14
• FST (REF. 60)
• Nei’s standard genetic distance57,58
• Change in above diversity statistics
• Longitudinal sampling
• Whole-exome and whole-genome 
sequencing
• Cell-free DNA analysis19
High
Low
Hazards (H) • Abundance of infiltrating 
lymphocytes82,83
• Morisita–Horn index of 
colocalization of cancer cells and 
lymphocytes75
• Signatures of immune 
activation82,83,101
• Density of pathogenic 
microorganisms99
• Prevalence of microbial virulence 
genes105
• Automated image analysis
• Immunohistochemistry
• RNA-Seq
• 16S rRNA sequencing
High
Low
Resources (R) • Degree of hypoxia146,149
• Density of blood vessels147,148
• Colocalization of cancer cells with 
fibroblasts160
• Concentration of ATP151, glucose 
and other nutrients
• Blood flow152,154
• Automated image analysis
• Immunohistochemistry
• MRI or PET–CT scans
• Intravenous induction of EF5
• Luciferase luminescence
• Mass spectrometry
Eco-index, ecological index; EF5, 2-(2-nitro-1-H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl) acetamide; Evo-index, evolutionary index; FISH, 
fluorescence in situ hybridization; FST, fixation index; MRI, magnetic resonance imaging; RNA-Seq, RNA sequencing; rRNA, ribosomal RNA; 
PET CT, positron emission tomography and computed tomography; SNP, singe nucleotide polymorphism.
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Table 2
An initial classification scheme
Type Icon Evo-index Eco-index Description
1 D1Δ1 H1R1 Like a desert, these tumours have few resources and little diversity. With low 
turnover, they are evolutionarily inert.
2 D1Δ1 H1R2 Much like normal tissue, these tumours have sufficient resources but evolve very 
slowly.
3 D1Δ1 H2R1 These tumours may have the best prognosis, with an immune response that 
probably helps to control the tumour, restricted resources and little capacity to 
evolve.
4 D1Δ1 H2R2 These tumours have ample resources but have also stimulated an antitumour 
immune response. However, they are otherwise evolutionarily inert.
5 D1Δ2 H1R1 These tumours are genetically homogeneous but are changing over time, perhaps 
through population bottlenecks or selective sweeps that re-homogenize the tumour.
6 D1Δ2 H1R2 These tumours are changing over time, potentially through homogenizing selective 
sweeps of new clones. While they may grow rapidly, with ample resources, their 
genetic homogeneity may make them vulnerable to therapy.
7 D1Δ2 H2R1 Predation by the immune system in these tumours may reduce genetic 
heterogeneity through selection against neo-antigens.
8 D1Δ2 H2R2 Natural selection may be driving the changes in these tumours and homogenizing 
them.
9 D2Δ1 H1R1 These tumours may be the result of the slow accumulation of clones over a long 
period of time or from exposure to mutagens.
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Type Icon Evo-index Eco-index Description
10 D2Δ1 H1R2 Like a garden, these tumours support a variety of clones, are well fed and are 
protected from hazards such as predation, but they change little over time.
11 D2Δ1 H2R1 Accumulation of many mutations may have led to an immune response in these 
tumours, but they appear to be otherwise restricted in their growth and evolution.
12 D2Δ1 H2R2 These genetically diverse tumours are changing only slowly, perhaps due to a low 
mutation rate or relatively weak selective pressures.
13 D2Δ2 H1R1 These tumours are evolving rapidly, generating and maintaining new clones at a 
high rate. They are probably under selective pressure for the ability to survive and 
proliferate with scarce resources or otherwise escape these resource constraints.
14 D2Δ2 H1R2 With potentially the worst prognosis, these genetically diverse tumours are 
evolving rapidly and have plenty of resources. They should have the highest 
capacity to evolve in response to interventions or other changes in their 
environment.
15 D2Δ2 H2R1 These rapidly evolving and diverse tumours are under the dual selective pressures 
of resource limitations and immune predation.
16 D2Δ2 H2R2 Like a rainforest, these genetically diverse tumours are changing rapidly, with a 
constant churn of new clones evolving and others going extinct. Resources are 
abundant, although they are probably being consumed rapidly, and predation from 
the immune system is extensive.
D, diversity; Δ, genetic, epigenetic or phenotypic change over time; Eco-index, ecological index; Evo-index, evolutionary index; H, hazards; R, 
resources.
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